Trial reportNature communications2023
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants.
Trial report in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 69 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Short Chain Fatty Acid Enhancing Prebiotics and Normalization of Parkinson's Disease Microbiome: A Pilot Tolerability Study
Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation
Fecal Microbiota Transplantation for the Treatment of Patients With Parkinson's Disease.
Who cites it
69 citing papers in PubMed, 6 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Global research trends in enteric nervous system and gut microbiota: a bibliometric analysis (2005-2025).Frontiers in cellular and infection microbiology · 2026Pooled it
- Gut-brain axis dysfunction in Parkinson's disease: a meta-analysis of microbiome dysbiosis and intestinal barrier markers.Frontiers in medicine · 2026Pooled it
- Beyond bacteria: a multi-omics view of the gut-brain axis in Parkinson's disease.Frontiers in cellular and infection microbiology · 2026Pooled it
- Gut microbiota signatures in mild cognitive impairment: a scoping review of microbial taxa and clinical implications.Frontiers in microbiology · 2026Pooled it
- The role of the gut microbiome in the progression of Parkinson's disease: a systematic review of patient cohorts.Journal of neurology · 2025Pooled it
- Mediterranean Diet Adherence, Gut Microbiota and Parkinson's Disease: A Systematic Review.Nutrients · 2024Pooled it
- Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study.Scientific reports · 2025Trial
- Inulin-induced improvements on bowel habit and gut microbiota in adults with functional constipation: findings of a randomized, double-blind, placebo-controlled study.BMC gastroenterology · 2025Trial
- Prebiotics and SCFA Alleviate Parkinson's-Related Constipation: Results from a Randomized Controlled Trial.Neurology and therapy · 2026Article
- Dietary supplements for Parkinson's disease: State of the science.Journal of Parkinson's disease · 2026Review
- Prebiotic intervention changes host and microbe proteomes in plasma extracellular vesicles of Parkinson's disease.Scientific reports · 2026Article
- Gut-Brain Signaling in Parkinson's Disease: A Narrative Review.International journal of molecular sciences · 2026Review
- Prebiotics attenuate depressive-like behavior, neuroinflammation and synaptic plasticity in Parkinson's disease by modulating butyrate-producing gut bacteria.Inflammopharmacology · 2026Article
- The gut as a central hub for multi-organ crosstalk in aging.Cellular and molecular life sciences : CMLS · 2026Review
- Gut microbiota and Parkinson's disease: exploring pathogenesis and potential therapeutic strategies from a gut-brain axis perspective.iScience · 2026Review
- Lifestyle medicine in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- The gut microbiota-short-chain fatty acid-inflammation axis in Parkinson's disease motor dysfunction: mechanisms and future of dietary interventions.Frontiers in neurology · 2026Review
- Unveiling Butyrate as a Parkinson's Disease Therapy.Neuroscience bulletin · 2026Review
- Differential gut microbiota modulation associated with anti-Parkinsonian effects ofFrontiers in nutrition · 2026Article
- Gut Microbiota and Dopamine: Producers, Consumers, Enzymatic Mechanisms, and In Vivo Insights.Bioengineering (Basel, Switzerland) · 2025Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
A pro-inflammatory intestinal microbiome is characteristic of Parkinson's disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.